PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
74.40%
Cash & equivalents yoy growth 0.75-0.9x RVPH's 95.93%. Bill Ackman might demand clarity on why growth lags the competitor's liquidity build.
No Data
No Data available this quarter, please select a different quarter.
74.40%
Cash + STI yoy 0.75-0.9x RVPH's 95.93%. Bill Ackman would wonder if competitor is building liquidity more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Other current assets growth 50-75% of RVPH's -54.11%. Bruce Berkowitz notes fewer expansions. Possibly simpler working capital.
70.82%
Similar yoy growth to RVPH's 72.84%. Walter Schloss notes comparable short-term expansions. Investigate quality of these assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.82%
Similar yoy to RVPH's 64.40%. Walter Schloss sees parallel expansions. Evaluate the quality of these assets.
72.56%
Above 1.5x RVPH's 5.25%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-50.51%
Similar yoy changes to RVPH's -49.51%. Walter Schloss finds a parallel approach to short-term funding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.03%
Exceeding 1.5x RVPH's 8.21%. Michael Burry suspects ballooning short-term obligations vs. competitor.
36.12%
Above 1.5x RVPH's 4.94%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.12%
Above 1.5x RVPH's 4.83%. Michael Burry sees a potential leverage warning sign.
10.25%
Less than half of RVPH's 45.49%. David Dodd sees fewer share issuances vs. competitor.
-4.93%
1.25-1.5x RVPH's -3.55%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
247.64%
≥ 1.5x RVPH's 89.71%. David Dodd sees stronger capital base growth than competitor.
70.82%
Similar yoy to RVPH's 64.40%. Walter Schloss sees parallel expansions in total capital.
No Data
No Data available this quarter, please select a different quarter.
-50.51%
Similar yoy changes to RVPH's -49.51%. Walter Schloss notes parallel total debt strategies.
-77.35%
Similar yoy changes to RVPH's -102.37%. Walter Schloss sees parallel net leverage strategies.